STAT3d
Purified T cell transplant lowers risk of immune reaction for blood cancer patients, study shows
A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...
CURE1d
Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Blood cancers dominate CAR-T pipeline
Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...
The Brighterside of News on MSN8d
New CAR-T therapy achieved complete remission in 70% of aggressive cancer patients
CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...
Sacramento doctor: If not for NIH funding, I wouldn’t have survived my leukemia diagnosis | Opinion
My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...
Interesting Engineering on MSN9d
US researchers develop next-gen CAR-T therapy to kill hard-to-treat cancers
CART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of ...
Earth.com9d
Study learns how cancer cells highjack the immune system
Researchers uncover how leukemia drains T cells' energy, paving the way for stronger cancer immunotherapy and enhancing CAR T ...
Fierce Biotech3d
Orca's cell therapy trounces traditional care in blood cancer phase 3, swimming into space's 'holy grail'
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...